Yan Hede, Black David, Jones Nicholas I, McCraw John, Chen Henan, Arnold Peter, Zhang Feng
Division of Plastic Surgery, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Ann Plast Surg. 2011 Sep;67(3):299-302. doi: 10.1097/SAP.0b013e3181fabc32.
In this study, the feasibility of Integra acellular collagen used as a vascular carrier in skin flap prefabrication was examined. In all, 20 Sprague--Dawley rats were randomly divided into 3 groups. The saphenous vascular bundle was used as the vascular carrier. In group 1 (n = 8), an arteriovenous fistula was made by anastomosis of distal saphenous artery and vein. An Integra patch (2 × 3 cm²) was placed underneath the vascular bundle. In group 2 (n = 6), an Integra patch was placed on the top of the saphenous vessels, which remained intact. In group 3 (n = 6), an arteriovenous fistula was made without Integra implant. Two weeks after the initial management, a skin flap (2 × 3 cm² in size) was raised and replaced in each group. The survival of the flaps and histology were evaluated at 7 days after flap replacement. The results showed that the average survival area in group 1 was 98% ± 2%. No flap survival was observed in group 2. The mean survival area in group 3 was 29% ± 6%. The differences among all 3 groups were significant (P < 0.05). Although the mean survival area in group 3 was significantly lower than that in group 1 (P < 0.001), it was significantly higher than that in group 2. Histology showed that the Integra patch was incorporated into the adjacent connective tissue, and increased amounts of neovascularization were seen between the collagenous sheets and dermis in group 1. In conclusion, this study demonstrated that Integra acellular collagen can incorporate into the adjacent tissue as a vascular carrier and induce angiogenesis in flap prefabrication. This biomaterial can provide a scaffold for supporting and enhancing the survival of a vascular prefabricated skin flap. The results indicate that this material is an ideal biomaterial for flap prefabrication and may be used for this clinical purpose in the future.
在本研究中,检验了Integra脱细胞胶原用作皮瓣预制中血管载体的可行性。总共20只Sprague-Dawley大鼠被随机分为3组。采用隐静脉血管束作为血管载体。第1组(n = 8),通过吻合隐静脉远端动脉和静脉制作动静脉瘘。将一块Integra补片(2×3 cm²)置于血管束下方。第2组(n = 6),将一块Integra补片置于完整的隐静脉血管上方。第3组(n = 6),制作动静脉瘘但不植入Integra。初始处理两周后,每组掀起并替换一块大小为2×3 cm²的皮瓣。在皮瓣替换后7天评估皮瓣存活情况及组织学表现。结果显示,第1组皮瓣平均存活面积为98%±2%。第2组未观察到皮瓣存活。第3组皮瓣平均存活面积为29%±6%。3组之间差异有统计学意义(P < 0.05)。虽然第3组皮瓣平均存活面积显著低于第1组(P < 0.001),但显著高于第2组。组织学检查显示,Integra补片融入相邻结缔组织,第1组胶原片层与真皮之间可见更多新生血管。总之,本研究表明,Integra脱细胞胶原可作为血管载体融入相邻组织并在皮瓣预制中诱导血管生成。这种生物材料可为支持和提高血管预制皮瓣的存活提供支架。结果表明,这种材料是皮瓣预制的理想生物材料,未来可能用于该临床用途。